ENSC vs. KZIA, ARTL, PTPI, PXMD, LIPO, SNGX, GNPX, PCSA, DRUG, and ZVSA
Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Kazia Therapeutics (KZIA), Artelo Biosciences (ARTL), Petros Pharmaceuticals (PTPI), PaxMedica (PXMD), Lipella Pharmaceuticals (LIPO), Soligenix (SNGX), Genprex (GNPX), Processa Pharmaceuticals (PCSA), Bright Minds Biosciences (DRUG), and ZyVersa Therapeutics (ZVSA). These companies are all part of the "pharmaceutical preparations" industry.
Kazia Therapeutics (NASDAQ:KZIA) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.
Kazia Therapeutics has a net margin of 0.00% compared to Kazia Therapeutics' net margin of -476.29%. Ensysce Biosciences' return on equity of 0.00% beat Kazia Therapeutics' return on equity.
In the previous week, Kazia Therapeutics had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 1 mentions for Kazia Therapeutics and 0 mentions for Ensysce Biosciences. Kazia Therapeutics' average media sentiment score of 0.00 beat Ensysce Biosciences' score of -1.00 indicating that Ensysce Biosciences is being referred to more favorably in the news media.
Ensysce Biosciences has a consensus target price of $7.00, suggesting a potential upside of 1,172.26%. Given Kazia Therapeutics' higher probable upside, analysts clearly believe Ensysce Biosciences is more favorable than Kazia Therapeutics.
Kazia Therapeutics received 75 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. However, 60.00% of users gave Ensysce Biosciences an outperform vote while only 52.35% of users gave Kazia Therapeutics an outperform vote.
30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 39.4% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Ensysce Biosciences has higher revenue and earnings than Kazia Therapeutics.
Kazia Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
Summary
Kazia Therapeutics beats Ensysce Biosciences on 8 of the 15 factors compared between the two stocks.
Get Ensysce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ensysce Biosciences Competitors List
Related Companies and Tools
